Public HealthIntellectual property, drug licensing, freedom of information, and public health
References (19)
Secrecy of drug regulation
Int J Risk Safety Med
(1996)- et al.
Too soon to market
BMJ
(1997) Hard to swallow
Guardian
(23 April 1998)The role of clinical research in the drug development process
Study information submitted by drug companies to licensing authorities
BMJ
(1980)All about albumin: biochemistry, genetics and medical applications
(1996)ABPI compendium of data sheets and summaries of product characteristics 1998–99
(1998)Review sparks controversy over human albumin therapy
Lancet
(1998)Albumin administration in critically ill patients (Cochrane Review)
The Cochrane Library
(1998)
There are more references available in the full text version of this article.
Cited by (18)
Guidelines for the Clinical Use of Albumin: Comparison of Use in Two Italian Hospitals and a Third Hospital Without Guidelines
2003, Current Therapeutic Research - Clinical and ExperimentalFreedom of information [15]
1998, LancetDissemination and publication of research findings: An updated review of related biases
2010, Health Technology AssessmentPatients and the public deserve big changes in evaluation of drugs
2009, BMJ (Online)Sequestered evidence and the distortion of clinical practice guidelines
2009, Perspectives in Biology and MedicineDevelopment of Marketing Authorisation Procedures for Pharmaceuticals
2007, Evaluating Pharmaceuticals for Health Policy and Reimbursement
Copyright © 1998 Elsevier Ltd. All rights reserved.